At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 148 enrolled
Drug / intervention
CP-690,550 or Placebo +1 moredrug
Likely dose
CP-690,550 or Placebo 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Placebo-Controlled, Two-Period, Fixed Sequence Study To Evaluate The Effect Of CP-690,550 On Measured Glomerular Filtration Rate In Patients With Active Rheumatoid Arthritis
In Brief
A Phase 1 clinical trial evaluating CP-690,550 or Placebo and Placebo for Arthritis, Rheumatoid. Completed, enrolled 148 participants across 24 sites in 8 countries.
Detailed Summary
The purpose of study is to explore the effect of CP-690,550 (Tofacitinib) on measures of kidney function in patients with active rheumatoid arthritis (RA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesCzechia, Germany, Mexico, Poland, Russia, South Korea, Spain, United States
Collaborators--
Timeline
Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartApr 2012
Primary CompletionJan 2013
Study CompletionFeb 2013
TodayJul 2026
First PostedDec 2, 2011
Enrollment StartApr 1, 2012
Primary CompletionJan 1, 2013
Study CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.6 years ago
Interventions
CP-690,550 or Placebodrug
CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
Placebodrug
Placebo BID orally, approximately 72 days